Payment overview · 2025
General Payments
$4,785.00
168 reported records · 30 companies
Healthcare provider profile · identity verified
Amir Salim, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WEBSTER, TX · NPI 1619901006
Verified facts
What the public records show
CMS Open Payments records show Amir Salim, M.D. received $4,785.00 in general payments during 2025 across 168 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xyosted by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $879.26 | 18.4% | 18 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $514.64 | 10.8% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $488.53 | 10.2% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $463.02 | 9.7% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $454.77 | 9.5% | 19 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $409.87 | 8.6% | 15 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $244.27 | 5.1% | 7 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $222.34 | 4.7% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $180.33 | 3.8% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $118.44 | 2.5% | 9 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $100.00 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $87.87 | 1.8% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $64.11 | 1.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.95 | 1.3% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $60.68 | 1.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.96 | 1.2% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $47.81 | 1.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $45.95 | 1.0% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.63 | 0.8% | 2 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $38.89 | 0.8% | 2 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $35.41 | 0.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.74 | 0.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $20.82 | 0.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.03 | 0.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.96 | 0.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.59 | 0.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.00 | 0.3% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $14.27 | 0.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.86 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,785.00 | 168 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $602.14 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $518.61 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $514.64 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $409.87 | 15 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $334.35 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $331.23 | 17 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $318.77 | 17 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $254.39 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $244.27 | 7 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $222.34 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $196.25 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $183.18 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $165.02 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $148.09 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $89.38 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.79 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $72.37 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $64.11 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.95 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $60.68 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $58.96 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $58.96 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $58.96 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $49.02 | 3 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $47.81 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.95 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.63 | 2 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $38.89 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $35.53 | 3 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $35.41 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $3.85 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $3.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 128 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 34 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
128 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 344 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 62 |
| Ezetimibe | Ezetimibe | 201 | 61 |
| Metformin Hcl Er | Metformin Hcl | 182 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 52 |
| Lisinopril | Lisinopril | 160 | 40 |
| Losartan Potassium | Losartan Potassium | 158 | 46 |
| Ozempic | Semaglutide | 152 | 19 |
| Farxiga | Dapagliflozin Propanediol | 128 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 27 |
| Trazodone Hcl | Trazodone Hcl | 98 | 35 |
| Sertraline Hcl | Sertraline Hcl | 95 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 32 |
| Celecoxib | Celecoxib | 82 | 26 |
| Liothyronine Sodium | Liothyronine Sodium | 80 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 25 |
| Montelukast Sodium | Montelukast Sodium | 74 | 17 |
| Omeprazole | Omeprazole | 71 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 14 |
| Buspirone Hcl | Buspirone Hcl | 69 | 16 |
| Gabapentin | Gabapentin | 63 | 26 |
| Alprazolam | Alprazolam | 54 | 12 |
| Clonazepam | Clonazepam | 54 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 15 |
| Azithromycin | Azithromycin | 48 | 43 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Allopurinol | Allopurinol | 45 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 43 | 23 |
| Simvastatin | Simvastatin | 42 | 12 |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 12 |
| Cefuroxime | Cefuroxime Axetil | 39 | 35 |
| Testosterone Cypionate | Testosterone Cypionate | 35 | 11 |
| Synthroid | Levothyroxine Sodium | 34 | 11 |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 16 |
| Metformin Hcl | Metformin Hcl | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Famotidine | Famotidine | 29 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 13 |
| Progesterone | Progesterone, Micronized | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Np Thyroid | Thyroid,pork | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | 13 |
| Mupirocin | Mupirocin | 20 | 17 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Spironolactone | Spironolactone | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Temazepam | Temazepam | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Xyosted | Testosterone Enanthate | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,785.00 · 168 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, DAXXIFY, FARXIGA, GARDASIL 9, JARDIANCE, JATENZO, JOURNAVX, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NEFFY, NEXLETOL, NP Thyroid 60, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, TZIELD, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, Xelstrym, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error